Headlines about Illumina (NASDAQ:ILMN) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Illumina earned a news impact score of 0.24 on Accern’s scale. Accern also assigned media coverage about the life sciences company an impact score of 46.1562361284364 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Analysts’ Suggestions in the Limelight – Illumina (NASDAQ:ILMN) (nasdaqjournal.com)
- Illumina (ILMN) Lifted to Strong-Buy at Vetr (americanbankingnews.com)
- Circulating Tumor Cells Market Top Manufacturers by 2023: Thermo Fisher Scientific, Illumina, Agilent Technologies … (newspharmaceuticals.com)
- Investors watching Technical Indicators on Illumina, Inc. (ILMN) (wallstreetmorning.com)
- Illumina (ILMN) Stock Rating Upgraded by BidaskClub (americanbankingnews.com)
ILMN stock traded down $1.24 during trading on Friday, hitting $244.60. The company had a trading volume of 1,092,933 shares, compared to its average volume of 709,332. The company has a market capitalization of $36,075.94, a P/E ratio of 61.15, a PEG ratio of 3.28 and a beta of 0.89. Illumina has a fifty-two week low of $167.98 and a fifty-two week high of $256.64. The company has a quick ratio of 3.55, a current ratio of 3.99 and a debt-to-equity ratio of 0.43.
Several analysts have weighed in on ILMN shares. BidaskClub upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. Piper Jaffray restated a “buy” rating and set a $269.00 price target on shares of Illumina in a research report on Tuesday, January 9th. Deutsche Bank set a $275.00 price target on shares of Illumina and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Canaccord Genuity restated a “buy” rating and set a $265.00 price target (up previously from $255.00) on shares of Illumina in a research report on Wednesday, January 31st. Finally, Citigroup upgraded shares of Illumina from a “neutral” rating to a “buy” rating and upped their price target for the stock from $260.00 to $275.00 in a research report on Monday, February 5th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $243.03.
In related news, Director Robert S. Epstein sold 1,250 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $244.18, for a total value of $305,225.00. Following the completion of the sale, the director now owns 8,588 shares of the company’s stock, valued at $2,097,017.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director A Blaine Bowman sold 3,000 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $230.82, for a total transaction of $692,460.00. Following the completion of the sale, the director now directly owns 19,868 shares of the company’s stock, valued at approximately $4,585,931.76. The disclosure for this sale can be found here. Insiders sold 18,008 shares of company stock valued at $4,130,075 in the last ninety days. Corporate insiders own 0.54% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.chaffeybreeze.com/2018/04/21/illumina-ilmn-earns-daily-media-impact-rating-of-0-24.html.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.